Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

The DOD can’t scale up defense specific biotech products – “valley of death” ensures the private sector won’t cooperate

Dieuliis 18 (Diana, Senior Research Fellow at the Center for the Study of Weapons of Mass Destruction and leads studies on biosecurity, biodefense and the synthetic biology industry. Dr. DiEuliis is a biologist by training and served for over two decades in various capacities at the Department of Health and Human Services and the Office of Science and Technology Policy at the White House. “BIOTECHNOLOGY FOR THE BATTLEFIELD: IN NEED OF A STRATEGY” https://warontherocks.com/2018/11/biotechnology-for-the-battlefield-in-need-of-a-strategy/)LR

Acquiring Biotech and the ‘Valley of Death’ Even if all needs for biotechnology were clear, the Defense Department would still need to improve the way it acquires biotechnology for the battlefield. Which capabilities should continue to be built in the department’s service research labs, and which ought to be acquired from external companies? One option is to simply adopt useful commercial products off the shelf as they are innovated in the private sector, particularly since many innovative biological materials can be dual-purposed for both consumers and the military. For example, in addition to its promise as lightweight body armor, spider silk can be used in ordinary clothing, textiles, construction materials, and novel medicines. Alternatively, the Defense Department could ask the private sector to create defense-specific products from the ground up. A third option is to generate prototype products within the department, then use the private sector to scale and deliver them. Right now, the inability to scale up synthetic biology products from prototypes is a bottleneck hindering the broad adoption of biotechnology and the private sector is already investing in scaling solutions — whether for commercial markets or defense. While the answer is likely a combination of all these approaches, the Defense Department needs to communicate clearly with biotechnology performers, since the private sector is not likely to make choices for manufacturing products for national security on its own. The well-recognized “valley of death” that prevents technological innovations from being translated into medicines, equipment, and warfighter benefits is a problem much broader than biotechnology. Since World War II, there has been a steady decline in the defense industrial base, as fewer companies are able to provide products specific to defense. Supply chains have become burdensome and unwieldy. For example, the successful genetic engineering of silk worms to make “dragon silk” for warfighters is promising. But producing dragon silk at scale will require thousands of silkworms — which in turn require a large acreage of mulberry trees not readily available in the United States. The company creating dragon silk hopes to use farming cooperatives in Vietnam to resolve the problem, but this will perpetuate the same kind of burdensome and costly supply chain that plagues defense acquisitions — working through foreign company contracts and embassies, and generating potential single points of failure through reliance on sole suppliers outside the country. To reduce these types of inefficiencies, defense planners must envision biotechnology products from inception through their full development and manufacture pathways that allow these technologies to be successfully shepherded through nimbler and more secure industrial supply chains. The “valley of death” also prevents technology companies from seeing the Defense Department as an attractive customer. The Pentagon’s traditional models for acquisition tend to be time-consuming and less cost-effective than commercial contracts. Recently, a report commissioned by the president on the state of the U.S. industrial base described the uncertainty of federal spending, the unintended consequences of government acquisition behavior, and the loss of skills in the domestic workforce as “unprecedented” challenges to defense manufacturing. America’s global competitors could be closing the technology gap because of process failures, rather than a lack of technology talent or innovative ideas.

Sign in to recut, update, or save this card.